• Isabella Márcia Soares Nogueira Teotônio, Juliana Lott de Carvalho, Luiz Cláudio Castro, Nadjar Nitz, Luciana Hagström, Geraldo Gonçalves Rios, Maria de Fátima Rodrigues de Oliveira, Bruno Stéfano Lima Dallago, and Mariana Hecht.
• Interdisciplinary Laboratory of Biosciences, Faculty of Medicine, University of Brasília, Brasília, Brazil; Nucleus of clinical pathology of Planaltina Regional Hospital, DF.
• Acta Trop. 2021 Feb 1; 214: 105782.

AbstractOriginated in Wuhan, China, the coronavirus 19 disease (COVID-19) has quickly spread worldwide, reaching countries that already faced other endemics and epidemics. In Brazil, such a concerning situation includes arboviruses, among which the dengue virus stands out. Here, we determined the rate of SARS-CoV-2/dengue virus co-infection in a total of 178 patients with COVID-19 symtoms admitted into a large public hospital of the Federal District of Brazil. Furthermore, we evaluated whether prior or active dengue virus infection influenced hematological, biochemical, and clinical parameters of such patients. One hundred and twelve (63%) individuals tested positive for COVID-19, of which 43 (38.4%) were co-infected with dengue virus, and 50 (44.6%) had antibodies indicative of previous dengue infection. Co-infected patients showed lower numbers of circulating lymphocytes and monocytes, higher glucose rates, and a worse pulmonary condition. Of note, prior infections with dengue virus did not influence clinical parameters, but active dengue fever resulted in higher hospitalization rate. In conclusion, amid the current complex epidemiological scenario in Brazil, our data support the notion that SARS-CoV-2 and dengue co-infection affects an important percentage of COVID-19 patients and leads to worse clinical parameters, requiring greater attention from health authorities.Copyright © 2020. Published by Elsevier B.V.

38 keywords...

hide…